COMPANY

Mirecule Inc.

HQ: Gaithersburg, MD source · mirecule.com ↗ · Mid-Atlantic

miRecule™ is a biotechnology company developing RNA therapies for cancer and muscular dystrophy. From company website Source · Oct 12, 2026

Keywords: cancer

Location: Gaithersburg, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

10NIH grants

Funding and NIH signals

NIH award NIH awarded $609K (SBIR Phase II 5R44NS119147-05, continuation, notice Sep 4, 2026). NIH RePORTER 5R44NS119147-05 (Sep 4, 2026)
Evidence (1 event)
- Sep 4, 2026 · NIH RePORTER 5R44NS119147-05
  Organization: MIRECULE, INC.; City/State: Gaithersburg, MD; Project number: 5R44NS119147-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 608751; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Deal Sanofi deal · amount not disclosed · announced Mar 18, 2026 Company release ↗
Source quote
- Mar 18, 2026 · Company release ↗
  “GAITHERSBURG, Md.–( BUSINESS WIRE )–Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Sep 4, 2026 Grant Government grant — SBIR: $608,751 (annual award, as published), announced Sep 4, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Jul 30, 2026 Partnership Partnership / licensing announced Jul 30, 2026. Source: company's own press page. source ↗
Mar 18, 2026 Partnership Partnership / licensing announced Mar 18, 2026. Source: company's own press page. source ↗
Sep 12, 2025 Grant Government grant — SBIR: $896,878 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Aug 13, 2025 Grant Government grant — SBIR: $1.23M (annual award, as published), announced Aug 13, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Funding

Last 2 years.

Jul 30, 2026 Partnership / licensing announced Jul 30, 2026. Source: company's own press page. source ↗
Mar 18, 2026 Partnership / licensing announced Mar 18, 2026. Source: company's own press page. source ↗
Sep 4, 2026 Government grant — SBIR: $608,751 (annual award, as published), announced Sep 4, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Sep 12, 2025 Government grant — SBIR: $896,878 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Aug 13, 2025 Government grant — SBIR: $1.23M (annual award, as published), announced Aug 13, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

NIH awards 10

Annual award amounts. Total $5.5M.

Sep 18, 2024 NIH award 1R44CA291527-01A1 FY2024: $863,708 awarded for that fiscal year; activity R44 (SBIR); PI SALEH, ANTHONY D; recipient as written: MIRECULE, INC., Gaithersburg, MD. Development of an antibody-oligonucleotide source ↗
Sep 17, 2024 NIH award 4R44NS119147-03 FY2024: $1,159,302 awarded for that fiscal year; activity R44 (SBIR); PI SALEH, ANTHONY D; recipient as written: MIRECULE, INC., Gaithersburg, MD. A Novel RNA Therapeutics Platform to Treat source ↗
Aug 19, 2022 NIH award 5R44NS119147-02 FY2022: $368,681 awarded for that fiscal year; activity R44 (SBIR); PI SALEH, ANTHONY D; recipient as written: MIRECULE, INC., Gaithersburg, MD. A Novel RNA Therapeutics Platform to Treat Fa source ↗
Sep 21, 2021 NIH award 1R44NS119147-01A1 FY2021: $370,531 awarded for that fiscal year; activity R44 (SBIR); PI SALEH, ANTHONY D; recipient as written: MIRECULE, INC., Gaithersburg, MD. A Novel RNA Therapeutics Platform to Treat source ↗
Jun 3, 2021 NIH award 5U44CA221567-03 FY2021: $1,000,000 awarded for that fiscal year; activity U44 (SBIR); PI SALEH, ANTHONY D; recipient as written: MIRECULE, INC., Gaithersburg, MD. Novel Targeted Nanomedicine Delivering Micr source ↗
Jun 26, 2020 NIH award 2U44CA221567-02A1 FY2020: $1,000,000 awarded for that fiscal year; activity U44 (SBIR); PI PLACE, ROBERT F; recipient as written: MIRECULE, INC., Gaithersburg, MD. Novel Targeted Nanomedicine Delivering Mic source ↗
Jul 10, 2019 NIH award 3U43CA221567-01S2 FY2019: $61,463 awarded for that fiscal year; activity U43 (SBIR); PI PLACE, ROBERT F; recipient as written: MIRECULE, INC., Gaithersburg, MD. A Novel Targeted Nanomedicine Delivering Micr source ↗
Jun 20, 2018 NIH award 3U43CA221567-01S1 FY2018: $49,951 awarded for that fiscal year; activity U43 (SBIR); PI PLACE, ROBERT F; recipient as written: MIRECULE, INC., Gaithersburg, MD. A Novel Targeted Nanomedicine Delivering Micr source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 272201800034C-0-0-1 FY2018: $305,000 awarded for that fiscal year; activity N01 (OTHER_NIH); PI SALEH, ANTHONY; recipient as written: MIRECULE, INC., Gaithersburg, MD. Development of a source ↗
Sep 22, 2017 NIH award 1U43CA221567-01 FY2017: $299,267 awarded for that fiscal year; activity U43 (SBIR); PI PLACE, ROBERT F; recipient as written: MIRECULE, INC., Gaithersburg, MD. A Novel Targeted Nanomedicine Delivering Micro source ↗